首页> 外文期刊>traditional medicine research >Exploring a novel traditional Chinese medicine prescription containing Chrysanthemi Flos for retinal diseases: an integrated strategy of data mining and network pharmacology
【24h】

Exploring a novel traditional Chinese medicine prescription containing Chrysanthemi Flos for retinal diseases: an integrated strategy of data mining and network pharmacology

机译:一种含菊花治疗视网膜疾病的新型中药方剂探索:数据挖掘与网络药理学的一体化策略

获取原文
获取原文并翻译 | 示例

摘要

Background: The severe visual damage or blindness is usually mainly caused by retinal diseases in all age groups. Traditional Chinese medicine (TCM) prescriptions containing Chrysanthemi Flos are commonly used for brightening eyes and have shown good clinical value for treating retinal diseases. This study aimed to screen a novel TCM prescription against retinal diseases based on patents containing Chrysanthemi Flos and explores its medication rule and mechanism using data mining, network pharmacology, molecular docking and molecular dynamics simulation. Methods: Data mining approach was used to screen a novel TCM prescription against retinal diseases and explore its medication rule. The mechanism of the novel TCM prescription against retinal diseases was revealed by constructing the network of TCMs-core active ingredients -core targets -core pathways using network pharmacology. Molecular docking and molecular dynamics simulation were performed to confirm the binding ability between core active ingredients and core targets. Results: TCM prescriptions with clearing heat and supplementing activities were applied most to treat three types of retinal diseases including glaucoma, diabetic retinopathy and age -related macular degeneration. These TCM prescriptions mainly possessed bitter and cold properties and were associated with the liver and lung meridians. A novel TCM prescription consisting of Chrysanthemi Flos, Cassiae Semen, Lycii Fructus, Angelicae Sinensis Radix and Salviae Miltiorrhizae Radix et Rhizoma was screened for the first time. Eighteen compounds were found to be the core active ingredients, modulating sixteen core targets including STAT3, MAPK3, AKT1, PIK3CA, EGFR and TP53, which may involve fifteen core pathways such as the AGE -RAGE signaling pathway in diabetic complications, MAPK signaling pathway, PI3K-Akt signaling pathway, HIF-1 signaling pathway and EGFR tyrosine kinase inhibitor resistance. Molecular docking and molecular dynamics simulation showed a strong binding affinity between almost all of the core active ingredients and targets. Conclusion: The novel TCM prescription has the potential to treat retinal diseases by inhibiting the inflammatory response, oxidative stress, retinal neovascularization, and apoptosis of retinal ganglion cells and retinal pigment epithelium cells as well as ameliorating retinal structural impairment through core targets and signaling pathways. This is the first study to screen a novel TCM prescription against retinal diseases, and provides reliable evidence and promising directions for new drug development.
机译:背景:严重的视力损伤或失明通常主要由所有年龄组的视网膜疾病引起。含有菊花的中医处方通常用于提亮眼睛,在治疗视网膜疾病方面显示出良好的临床价值。本研究旨在筛选一种基于含菊花专利的治疗视网膜疾病的新型中药方,并利用数据挖掘、网络药理学、分子对接和分子动力学模拟等方法,探索其用药规律和作用机制。方法:采用数据挖掘方法筛选出一种针对视网膜疾病的新型中医处方,并探讨其用药规律。通过运用网络药理学构建中药核心活性成分-核心靶点-核心通路网络,揭示了中药治疗视网膜疾病的新型处方机制。通过分子对接和分子动力学模拟,确认了核心活性成分与核心靶点的结合能力。结果:清热辅食中医方剂对青光眼、糖尿病视网膜病变和年龄相关性黄斑变性3类视网膜疾病的治疗应用最多。这些中药方主要具有苦寒性状,与肝经、肺经有关。首次筛选出由菊花、决明子精液、捔梗、当归和丹参组成的新型中药方剂,包括菊花、决明精、枸杞、当归、丹参、丹发现18种化合物为核心活性成分,调节STAT3、MAPK3、AKT1、PIK3CA、EGFR和TP53等16个核心靶点,可能涉及糖尿病并发症中的AGE -RAGE信号通路、MAPK信号通路、PI3K-Akt信号通路、HIF-1信号通路和EGFR酪氨酸激酶抑制剂耐药等15个核心通路。分子对接和分子动力学模拟表明,几乎所有核心活性成分与靶点之间都具有很强的结合亲和力。结论:该中药新方通过抑制视网膜神经节细胞和视网膜色素上皮细胞的炎症反应、氧化应激、视网膜新生血管形成和凋亡,以及通过核心靶点和信号通路改善视网膜结构损伤,具有治疗视网膜疾病的潜力。这是首个筛选出针对视网膜疾病的新型中药方剂的研究,为新药开发提供了可靠的证据和有希望的发展方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号